Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.54 |
| ▸ | TNK2 | Q07912 | 9/20 | 0.49 |
| ▸ | RAF1 | P04049 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8402298 | 0.89 | BTK (0.45) | BTKTNK2RAF1SRC | |
| SCHEMBL10240981 | 0.88 | RAF1 (0.59) | BTKTNK2RAF1SRCIGF1R | |
| SCHEMBL10241497 | 0.87 | RAF1 (0.47) | BTKTNK2RAF1SRCPDPK1 | |
| SCHEMBL8399399 | 0.85 | RAF1 (0.45) | BTKTNK2RAF1SRC | |
| SCHEMBL10242091 | 0.85 | TNK2 (0.51) | BTKTNK2RAF1SRCIGF1R | |
| SCHEMBL10241498 | 0.85 | RAF1 (0.46) | BTKTNK2RAF1SRC | |
| SCHEMBL8410126 | 0.84 | TNK2 (0.43) | BTKTNK2RAF1SRC | |
| SCHEMBL10240965 | 0.83 | TNK2 (0.48) | BTKTNK2RAF1SRCIGF1R | |
| SCHEMBL8399662 | 0.83 | TNK2 (0.49) | BTKTNK2RAF1SRCIGF1R | |
| SCHEMBL8396331 | 0.82 | TNK2 (0.47) | TNK2RAF1SRCIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923555-B2 | Fused bicyclic mTor inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | BTK 564/4885TNK2 669/4885RAF1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.